During Thursday’s trading session, shares of one of the 10 leading fixed-dosage injectable manufacturers in the world surged nearly 5 percent on BSE, after securing Ukrainian GMP renewal, further strengthening its global pharmaceutical footprint.
With a market cap of Rs. 474.5 crores, the shares of Venus Remedies Limited closed in the green at Rs. 355 on BSE, up by nearly 2 percent, compared to its previous closing price of Rs. 349.3.
The stock has delivered positive returns of around 18 percent in one year, and has gained by over 5 percent in the last one month.
What’s the News
As per the latest regulatory filings with the stock exchanges, Venus Remedies Limited has successfully renewed its Good Manufacturing Practices (GMP) certification from Ukraine’s State Service on Medicines and Drugs Control (SMDC).
The certification applies to the company’s Unit-II manufacturing facility located in Baddi, Himachal Pradesh, covering its cephalosporin, nor-cephalosporin (carbapenem), and oncology parenteral production lines, including liquid and lyophilised injections.
The certification strengthens the company’s position in PIC/S markets, reinforcing its commitment to global quality standards. Venus Remedies already has a robust presence in 32 PIC/S countries, including South Africa, Thailand, Malaysia, Saudi Arabia, and Australia. The Ukrainian pharmaceutical market, projected to grow at a CAGR of 3.9 percent and reach $822.26 million by 2029.
Venus Remedies, with over two decades of experience in Ukraine and 44 product registrations to date, views this certification as pivotal for sustained growth and expanded access within the broader Asia Commonwealth of Independent States (CIS) region.
Financial Performance
Venus Remedies reported a growth in revenue from operations, experiencing a rise of nearly 24 percent YoY, increasing from Rs. 143 crores in Q3 FY24 to Rs. 177 crores in Q3 FY25. Similarly, its net profit increased during the same period from Rs. 7 crores to Rs. 20 crores, indicating an impressive rise of around 186 percent YoY.
About the Company
Venus Remedies Limited is one of the handful players in the pharmaceutical sector to launch injectables globally. It has world-class manufacturing facilities in Panchkula and Baddi (in India), and an R&D centre under the name of Venus Medicine Research Centre (in India). The company is mainly engaged in I/V fluids and injectables, ceftazidime, amlodipine, gliclazide, lisinopril, and more.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
